Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?

Sophie Liabeuf(Centre Hospitalier Universitaire Amiens-Picardie), Marion Pépin(Inserm), Casper Franssen(University Medical Center Groningen), Davide Viggiano(University of Campania "Luigi Vanvitelli"), Sol Carriazo(Hospital Universitario Fundación Jiménez Díaz), Ron T. Gansevoort(University Medical Center Groningen), Loreto Gesualdo(Research and Studies Telecommunications Centre), Gaye Hafez(Altınbaş University), Jolanta Małyszko(Medical University of Warsaw), Christopher Mayer(Austrian Institute of Technology), Dorothea Nitsch(London School of Hygiene & Tropical Medicine), Alberto Ortíz(Hospital Universitario Fundación Jiménez Díaz), Vesna Pešić(University of Belgrade), Andrzej Więcek(Medical University of Silesia), Ziad A. Massy(Inserm), CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target), Giovambattista Capasso, Alexandre Andrade, Maie Bachmann, Inga Arūnė Bumblytė, Adrian Covic, Pilar Delgado, Nicole Endlich, Andreas Engvig, Denis Fouque(University Medical Center Groningen), Casper Franssen(University Medical Center Groningen), Sebastian Frische, Liliana Gârneaţă(Research and Studies Telecommunications Centre), Loreto Gesualdo(University of Bari Aldo Moro), Konstantinos Giannakou, Dimitrios Goumenos, Ayşe Tuğba Kartal, Laila‐Yasmin Mani, Hans-Peter Marti(Austrian Institute of Technology), Christopher Mayer(Austrian Institute of Technology), Rikke Nielsen(University of Belgrade), Vesna Pešić(University of Belgrade), Merita Rroji, Giorgos K. Sakkas, Goce Spasovski, Kate Stevens, Evgueniy Vazelov(University of Campania "Luigi Vanvitelli"), Davide Viggiano(University of Campania "Luigi Vanvitelli"), Lefteris C. Zacharia, Ana Carina Ferreira(Medical University of Warsaw), Jolanta Malyszko(Medical University of Warsaw), Ewout J. Hoorn, Andreja Figurek, Robert J. Unwin, Carsten A. Wagner(Austrian Institute of Technology), Christoph Wanner, Annette Bruchfeld(CHU Ambroise Paré), Marion Pépin(Inserm), Andrzej Więcek(Medical University of Silesia), Dorothea Nitsch(London School of Hygiene & Tropical Medicine), Ivo Fridolin(Altınbaş University), Gaye Hafez(Altınbaş University), María José Soler Romeo, Michelangela Barbieri, Bojan Batinić, Laura Carrasco(Hospital Universitario Fundación Jiménez Díaz), Sol Carriazo(Hospital Universitario Fundación Jiménez Díaz), Ron T. Gansevoort(University Medical Center Groningen), Gianvito Martino, Francesco Mattace‐Raso, Ionuţ Nistor(Hospital Universitario Fundación Jiménez Díaz), Alberto Ortíz(Hospital Universitario Fundación Jiménez Díaz), Giuseppe Paolisso, Daiva Rastenytė, Gabriel Ştefan, Gioacchino Tedeschi(Centre de recherche en Epidémiologie et Santé des Populations), Ziad A. Massy(Inserm), Boris Bikbov, Karlhans Endlich(Centre Hospitalier Universitaire Amiens-Picardie), Olivier Godefroy(Centre Hospitalier Universitaire Amiens-Picardie), Jean‐Marc Chillon, Anastassia Kossioni, Justina Kurganaite, Norberto Perico, Giuseppe Remuzzi, Tomasz Grodzicki, Francesco Trepiccione, Carmine Zoccali, Mustafa Arıcı, Peter J. Blankestijn, Kai‐Uwe Eckardt, Danilo Fliser, Eugenio Gutiérrez Jiménez, Maximilian König, Ivan Rychlík, Michela Deleidi, György Reusz
Nephrology Dialysis Transplantation
August 2, 2021
Cited by 89Open Access
Full Text

Abstract

Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.


Related Papers

No related papers found

Powered by citation graph analysis